Phase 1 Clinical study of Oravax's COVID-19 vaccine
Latest Information Update: 11 Oct 2022
Price :
$35 *
At a glance
- Drugs COVID-19 vaccine-Oravax Medical (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man; Proof of concept
- 07 Oct 2022 Preliminary results (Cohort-1) presented in an Oramed Pharmaceuticals Media Release.
- 07 Jul 2022 According to an Oramed Pharmaceuticals media release, the company expect Cohort B to complete dosing this quarter as well, with data expected in Q4 2022.
- 07 Jul 2022 According to an Oramed Pharmaceuticals media release, due to several factors, including the fact that many volunteers did not qualify during screening due to prior asymptomatic COVID-19 infection and other conditions, the rate of enrollment was slower than anticipated. the company added an additional clinical site and we have since completed enrollment and dosing of Cohort A with no safety issues reported thus far and anticipate sharing top-line data this quarter.